DNA-Dependent Protein Kinase Inhibitor, EP3976624A1
Summary
The European Patent Office has published patent application EP3976624A1 titled 'DNA-Dependent Protein Kinase Inhibitor' for cancer therapy. The filing classifies under C07D 519/00 with A61K 31/519 and A61P 35/00 designations. Dizal (Jiangsu) Pharmaceutical Co., Ltd. is listed as applicant with five inventors named. The application designates 35 states including Germany, France, the United Kingdom, Italy, and Spain.
Pharmaceutical and biotech companies developing DNA-PK inhibitors or kinase-targeted cancer therapies should assess freedom-to-operate implications. The publication creates potential IP barriers for competitors in the DNA-PK cancer therapy space.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 31 changes logged to date.
What changed
The European Patent Office has published patent application EP3976624A1 for a DNA-dependent protein kinase inhibitor (DNA-PK) compound and its use in cancer therapy. The application is classified under C07D 519/00 (heterocyclic compounds) with secondary classifications for pharmaceutical preparations (A61K 31/519) and antineoplastic agents (A61P 35/00). Dizal (Jiangsu) Pharmaceutical Co., Ltd. is named as the applicant with five listed inventors.
Affected parties include pharmaceutical companies, biotech firms, and research institutions active in DNA-PK inhibitor development or kinase-targeted cancer therapies. The publication establishes priority date and creates potential freedom-to-operate considerations for competing developers in the DNA-PK cancer therapy space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DNA-DEPENDENT PROTEIN KINASE INHIBITOR
Publication EP3976624A1 Kind: A1 Apr 15, 2026
Applicants
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Inventors
QI, Changhe, TSUI, Honchung, ZENG, Qingbei, YANG, Zhenfan, ZHANG, Xiaolin
IPC Classifications
C07D 519/00 20060101AFI20230511BHEP A61K 31/519 20060101ALI20230511BHEP A61P 35/00 20060101ALI20230511BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.